网站标志
点评详情
发布于:2021-10-14 10:04:47  访问:44 次 回复:0 篇
版主管理 | 推荐 | 删除 | 删除并扣分
E primer binds the ATG region in the ORF. These sequences
The DNA fragment had been purified and size Title Loaded From File confirmed by 2 agarose gel electrophoresis (Qiagen). Normalized sample pools were submitted to sequencing applying band intensitiesGenes Cancerto quantify relative sample amounts. Targeting the area of DNA upstream of your 4-nt ORF barcode, the Illumina Sequencing Primer, ISP, was used to create a 27-nt Illumina HiSeq study containing the 4-nt barcode, a 17-nt linker sequence and ATG web-site and also the 6-nt index primer. For technical replication, every single sample was ready with two distinctive P7-reverse primers. We located that each the technical and biological replicates yielded comparable information with r2 = 0.9. For every one of a kind sequence representing the 4-nt ORF barcode as well as the 6-nt index primer, the number of reads was counted and the fractional representation inside the screen was determined by dividing by the total number of reads of each index primer (i.e. total variety of reads for each sample). Fractional representation in every technical and biological replicate was then calculated and averaged. Finally, the fractional representation of each drug treated sample was normalized for the fractional representation of every ORF in the car treated samples. To recognize hits, constructs whose representation was enriched in drug treated versus automobile treated samples had been identified. The cutoff for hit calling was defined because the presence of at the least a single activating construct per pathway conferring greater than 50 enrichment above controls across at least two drug concentrations, as constructs scoring at or above this level have been located to be reliably validated in secondary, eight-point growth inhibition 50 (GI50 assays).Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, et al. International network of cancer genome projects. Nature. 2010; 464(7291):993-998. two. 3. Garraway LA and Lander ES. Lessons from the cancer genome. Cell. 2013; 153(1):17-37. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-1500. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H. EGF receptor gene mutations are widespread in lung cancers from "never smokers" and are connected with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-13311. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA. Activating mutations inside the epidermal development factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-2139. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Pina V, et al.
共0篇回复 每页10篇 页次:1/1
共0篇回复 每页10篇 页次:1/1
我要回复
回复内容
验 证 码
看不清?更换一张
匿名发表 
脚注信息
版权所有 Copyright(C)2009-2016 鞋类商城成品网站演示